Drug
Methoxsalen clinical trials
Also written Uvadex.
- studies test it
- 19
- open now
- 4
- in phase 3
- 2
- first study started
- 1996
Keep track of what changes. Save the Methoxsalen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2002 (2)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 2
- 14
- Phase 3
- 2
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 10
Mallinckrodt (5) · Therakos LLC (2) · Universitätsklinikum Hamburg-Eppendorf (1) · Medical University of Graz (1) · M.D. Anderson Cancer Center (1) · National Center for Research Resources (NCRR) (1) · Therakos (1) · Central Hospital, Nancy, France (1)
Studies
Open first, then newest update. How each study uses Methoxsalen is read from its arms, and is right about nine times in ten.
Testing it · 19
- Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic SclerosisRecruitingPhase 2London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNCT04986605Written as UVADEX
- PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid ExposureNot yet recruitingPhase 2Therakos LLCNCT07619898Written as methoxsalen
- Photopheresis in Early-stage Mycosis FungoidesRecruitingPhase 2Columbia UniversityNCT05680558Written as UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis
- Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHDNot yet recruitingPhase 2Central Hospital, Nancy, FranceNCT06133192Written as Uvadex
- EPIC- Extracorporeal Photopheresis (ECP) for Immune-related ColitisWithdrawnPhase 2Therakos LLCNCT06646016Written as Methoxsalen
- Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host DiseaseActive, not recruitingPhase 2Universitätsklinikum Hamburg-EppendorfNCT04291261Written as Uvadex
- Study of Photopheresis in the Treatment of Erythrodermic MF and SSWithdrawnPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT03563040Written as Methoxsalen
- Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host DiseaseTerminatedPhase 3Therakos, Inc., a Mallinckrodt CompanyNCT02524847Written as Methoxsalen
- Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHDTerminatedPhase 2National Cancer Institute (NCI)NCT02322190Written as Methoxsalen
- Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)CompletedEarly Phase 1MallinckrodtNCT01380535Written as ECP Methoxsalen
- PUVA Maintenance Therapy in Mycosis FungoidesCompletedPhase 3Medical University of GrazNCT01686594Written as 8-methoxypsoralen
- Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2ACompletedPhase 4M.D. Anderson Cancer CenterNCT00221039Written as Methoxsalen+ECP
- Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host DiseaseCompletedPhase 2MallinckrodtNCT00054613Written as Methoxsalen
- Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host DiseaseCompletedPhase 2MallinckrodtNCT00054600Written as Methoxsalen
- Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's DiseaseCompletedPhase 2MallinckrodtNCT00221026Written as Methoxsalen +ECP
- Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid ArthritisCompletedPhase 2MallinckrodtNCT00221000Written as Methoxsalen
- Extracorporal Photopheresis Pilot StudyStatus unknownPhase 1/2Hospices Civils de LyonNCT00930566Written as methoxsalen
- Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa AcquisitaCompletedPhase 2National Center for Research Resources (NCRR)NCT00004359Written as methoxsalen
- The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related ComplexCompletedNot applicableTherakosNCT00002011Written as Methoxsalen
Given in every arm · 2 — Methoxsalen is usual care beside what is tested
- Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis FungoidesTerminatedPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT00056056Written as methoxypsoralen
- Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell TransplantCompletedPhase 2University of Michigan Rogel Cancer CenterNCT00639717Written as methoxsalen
Codes
What other systems call Methoxsalen · ClinicalTrials.gg INT007810
- MeSH (NLM) D008730MethoxsalenConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) U4VJ29L7BQMETHOXSALENConfirmed FDA, NLM, Wikidata
- RxNorm 6854Confirmed FDA, Wikidata
- Wikidata Q408570methoxsalenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C643MethoxsalenOne source FDA
- DrugBank DB00553One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D008730 | Methoxsalen | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | U4VJ29L7BQ | METHOXSALEN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 6854 | — | Confirmed FDA, Wikidata |
| Wikidata | Q408570 | methoxsalen | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C643 | Methoxsalen | One source FDA |
| DrugBank | DB00553 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.